Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage i non-small cell lung cancer

Cancer

Volumn 119, Issue 17, 2013, Pages 3123-3132

  Shah, Anand ^a,b   Hahn, Stephen M ^a   Stetson, Robert L ^a   Friedberg, Joseph S ^c   Pechet, Taine T V ^c   Sher, David J ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cost effectiveness; lobectomy; lung cancer; stereotactic body radiation therapy; surgery; wedge resection

Indexed keywords

AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HIDDEN MARKOV MODEL; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LOBECTOMY; LUNG NON SMALL CELL CANCER; MEDIASTINOSCOPY; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STEREOTACTIC BODY RADIATION THERAPY; VIDEO ASSISTED THORACOSCOPIC SURGERY; WEDGE RESECTION;

COST-EFFECTIVENESS; LOBECTOMY; LUNG CANCER; STEREOTACTIC BODY RADIATION THERAPY; SURGERY; WEDGE RESECTION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; MARKOV CHAINS; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; QUALITY-ADJUSTED LIFE YEARS; RADIOSURGERY; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY;

EID: 84882667252     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28131     Document Type: Article

References (26)

1. Siegel R, Naishadham D, Jemal A,. Cancer Statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009; 75: 677-682.
3. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303: 1070-1076.
4. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small-cell lung cancer. Int J Radiation Oncol Biol Phys. 2012; 83: 348-353.
5. Win T, Sharples L, Wells FC, et al. Effect of lung cancer surgery on quality of life. Thorax. 2005; 60: 234-238.
6. Grills IS, Mangona VS, Welsh R, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010; 28: 928-935.
7. Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010; 140: 377-386.
8. Carr SR, Schuchert MJ, Pennathur A, et al. Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg. 2012; 143: 390-397.
9. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010; 28: 35-42.
10. Doyle S, Lloyd A, Walker M,. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer. 2008; 62: 374-380.
11. Ramsey SD, Scoggins JF, Blough DK, McDermott CL, Reyes CM,. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. J Manag Care Pharm. 2009; 15: 659-668.
12. US Department of Labor. Bureau of Labor Statistics. CPI Inflation Calculator. http://www.bls.gov/data/inflation-calculator.htm. Cited June 21, 2012.
13. Weinstein MC, Skinner JA,. Comparative effectiveness and health care spending-implications for reform. N Engl J Med. 2010; 362: 460-465.
14. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011; 81: 1352-1358.
15. Doria-Rose VP, White MC, Klabunde CN, et al. Use of lung cancer screening tests in the United States: results from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1049-1059.
16. Sher DJ, Wee JO, Punglia RS,. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e767-e774.
17. Puri V, Crabtree TD, Kymes S, et al. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. J Thorac Cardiovasc Surg. 2012; 143: 428-436.
18. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008; 26: 4617-4625.
19. Allen MS, Darling GE, Pechet TT, et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006; 81: 1013-1020.
20. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J,; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350: 351-360.
21. Fernando HC, Landreneau RJ, Mandrekar SJ, et al. Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. J Thorac Cardiovasc Surg. 2011; 142: 1143-1151.
22. Red Book: Pharmacy's Fundamental Reference. New York, NY; Thomson Medical Economics; 2007.
23. A comprehensive cost analysis of Medicare home oxygen therapy: a study for the American Association for Homecare. Mechanicsburg, PA: Morrison Informatics; 2006.
24. Perez A, Touchette DR, DiDomenico RJ, Stamos TD, Walton SM,. Comparison of rate control versus rhythm control for management of atrial fibrillation in patients with coexisting heart failure: a cost-effectiveness analysis. Pharmacotherapy. 2011; 31: 552-565.
25. Lang K, Marciniak MD, Faries D, et al. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Value Health. 2009; 12: 481-488.
26. Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J,. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008; 6: 84.